On February 23, 2026, the Italian Medicines Agency (AIFA) published revised guidance clarifying the definition and classification of over-the-counter (OTC) and non-prescription (SOP) medicines in Italy. The update replaces prior Ministry of Health guidelines and affects pharmaceutical manufacturers, distributors, and stakeholders involved in product registration and commercialization.
Details of the Update
The new guidance introduces revised definitions and classification principles for OTC and SOP medicines, providing clearer criteria to distinguish products not subject to medical prescription. It also sets out regulatory requirements that apply to these categories, with implications for regulatory submissions, labeling practices, and market access strategies. Existing products may need to be reviewed or reclassified to align with the updated criteria.
Effective Date
The guidance becomes effective 30 days after publication of the Notice in the Official Journal of the Italian Republic that references the AIFA website release. Stakeholders must monitor the Official Journal to determine the exact compliance of the start date.
Why It Matters
By replacing earlier guidance and clarifying classification criteria, the update strengthens regulatory clarity and supports consistent compliance across OTC and SOP portfolios. Clearer definitions enable more efficient regulatory alignment and help minimize unnecessary burden while maintaining compliant labeling and market access pathways.
Who This Is Relevant For
This update is relevant for Quality Assurance, Regulatory Affairs, Legal and Compliance, Patient Safety, Commercial and Marketing, and R&D teams managing OTC and SOP products in Italy.
Next Steps
Stakeholders should monitor the Official Journal for the publication date, review current product portfolios against the revised criteria, and coordinate cross-functionally to identify any products requiring reclassification or updates to documentation and labeling.
As teams evaluate portfolio impacts and timelines tied to the Official Journal notice, RegASK can support proactive tracking and structured review. RegASK is a leading agentic AI regulatory intelligence and workflow orchestration platform that empowers global organizations in highly regulated sectors, including consumer products and life sciences, to proactively navigate complex regulatory landscapes. By combining advanced Agentic AI with experts in the loop, RegASK delivers timely predictive actionable insights and end-to-end automation, streamlining compliance processes, mitigating risks, and accelerating market access across more than 160 countries. Learn more or book a demo now.
FAQs
What is the scope of AIFA’s updated guidance on OTC and SOP medicines?
The guidance clarifies definitions, classification principles, and regulatory requirements for OTC and non-prescription medicines marketed in Italy.
When does the new AIFA guidance take effect?
It takes effect 30 days after the Notice is published in the Official Journal of the Italian Republic referencing the AIFA website release.
Which teams should assess the impact of this update?
Quality Assurance, Regulatory Affairs, Legal and Compliance, Patient Safety, Commercial and Marketing, and R&D teams should assess implications.
How can RegASK help organizations respond to this update?
RegASK can help teams monitor Official Journal publications, map products to updated criteria, and coordinate cross-functional reviews to ensure timely, compliant implementation.
Subscribe to the latest regulatory news
Curated newsletters
Relevant industry info
Access expert insights
